Galapagos Genomics NV to Supply Chemical Compound Sets to Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica N.V.

Mechelen, Belgium; 8 March 2007 - Galapagos NV (Euronext & LSE: GLPG) announced today that its service division, BioFocus DPI, has entered into an agreement to supply small molecule compounds for drug discovery to the Johnson & Johnson Pharmaceutical Research & Development Division of Janssen Pharmaceutica NV (J&JPRD). Under the terms of the two-year agreement, BioFocus DPI will provide access to compounds from its SoftFocus small molecule libraries and will also generate customer specific compound library sets for use in J&JPRD's drug discovery programs. Financial terms were not disclosed.

Back to news